Dexcom

Leading CGM Further

May 2017

1
 Safe Harbor Statement
This presentation contains forward-looking statements that are not purely historical
regarding DexComs or its managements intentions, beliefs, expectations and strategies for
the future. All forward-looking statements and reasons why results might differ included in
this presentation are made as of the date of this presentation, based on information currently
available to DexCom, deal with future events, are subject to various risks and uncertainties,
and actual results could differ materially from those anticipated in those forward-looking
statements. The risks and uncertainties that may cause actual results to differ materially
from DexComs current expectations are more fully described in DexComs annual report on
Form 10-K for the period ended December 31, 2016, as filed with the Securities and
Exchange Commission on February 28, 2017, its most recent quarterly report on Form 10-Q
for the period ended March 31, 2017, as filed with the Securities and Exchange Commission
on May 2, 2017, and its other reports, each as filed with the Securities and Exchange
Commission. DexCom assumes no obligation to update any such forward-looking statement
after the date of this report or to conform these forward-looking statements to actual results.
2
CGM & Diabetes
Management

3
Diabetes Management Ecosystem

Blood Glucose Meters

Continuous Glucose Monitoring
Other
Pens
Disposable Pumps
Durable Pumps and
Supplies
Algorithms
Outcome
Measurement
Decision Support &
Coaching

Clinicians
Insulins Hospitals
Other T2 Compounds Education
Other Medications

4
 INSULIN
INTENSIVE
(T1+T2)

Cardiovascular disease
Blindness
Kidney failure
Nerve degeneration

HEALTHY GLUCOSE RANGE

Diminished cognitive function

Loss of consciousness
Potential death

5
 INSULIN
INTENSIVE
(T1+T2)

70%
Of the time patients are
outside healthy range

6
1) Murata GH, Hoffman RM, Shah JH, Wendel CS, Duckworth WC: A probabilistic model for predictinghypoglycemia in type 2 diabetes mellitus: the Diabetes Outcomes in Veterans Study (DOVES). ArchIntern Med 2004;164:14451450
 Glucose (mg/dl)
Intermittent monitoring
350
is not enough.

280 SMBG*

120
210

140

HEALTHY GLUCOSE RANGE

80

0 2 4 6 8 10 12 14 16 18 20 22 24
Time (hours)

*Self Monitoring of Blood Glucose (SMBG) 7

 Glucose (mg/dl)
Intermittent monitoring
350
is not enough.
CGM

280
OVER 4 HOURS ABOVE 210 BEFORE SMBG

210

ABOVE 140 FOR 13.5 HOURS

140

HEALTHY GLUCOSE RANGE

80

DANGEROUS LOW FOR 1 HOUR

0 2 4 6 8 10 12 14 16 18 20 22 24
Time (hours)

*Self Monitoring of Blood Glucose (SMBG) 8

9
 Leading Performance Starts with Accuracy
G6 raises the bar

30%

25% 26% Dexcom System MARD*

by Generation
Accuracy (MARD) %

20%

17%
15%
16%

13%
10%
9% 9%
8%
5%

0%
STS 3-Day SEVEN SEVEN Plus G4 PLATINUM G5 Mobile G6 Single Cal G6 No Cal
(2006) (2007) (2008) (2012) (2015) (Pre-Pivotal) (Pre-Pivotal)

* Mean Absolute Relative Difference (MARD) between CGM readings and blood glucose readings 10
 Performance that drives outcomes
DIaMonD results published in JAMA demonstrated a 1.0% reduction in mean A1c from baseline with CGM alone3

1%-point or greater drop in A1c reduces

8.6% 8.6% long-term complication rates by ~40%1,2

8.2%
Mean HbA1c, %

8.1%

7.7%
7.6%

Baseline Week 12 Week 24

Usual care CGM

1) Diabetes 1996;45:1289-1298; Lancet. 1998; 352:837-853. 11

2) American Diabetes Association. Eeg-Olofsson K, et al "HbA1c reduction and risk of cardiovascular diseases in type 2 diabetes: An observational study from the swedish NDR" ADA 2012
3) JAMA. 2017;317(4):371-378
Dexcom is the leader in continuous glucose measurement

Our Strategy

Performance Adherence Cost

Industry leading Patient experience: Longer duration

performance expected New applicator, smaller sensors, next
to improve with G6 & size, ease-of-use generation
G7 Connectivity: Share, transmitter, Verily
Completely eliminate Android, insulin delivery Novel business
finger sticks & data integration models

12
Non-Adjunctive Claim
The first & only CGM approved by the FDA as a replacement for finger stick testing for
diabetes treatment decisions

13
 Dexcom has the only therapeutic CGM system covered by
Medicare

January 12, 2017 March 24, 2017

CMS announces the determination of a benefit
category and coverage for therapeutic CGM by
CMS
Dexcoms G5 Mobile CGM system is currently
the only CGM classified by the FDA as a non-
adjunctive / therapeutic device
CMS publishes article clarifying criteria for coverage
and coding of Dexcoms G5 Mobile CGM System
Patients with either Type 1 or Type 2 diabetes who
intensively manage their insulin are cleared to obtain
reimbursement under Medicare & Medicaid

14
 G6: Focused on the patient experience

G5 G6 G6 G6
2/day1 1/day1 1/day1 No Cal1
ALL DATA ADULTS ALL DATA

N 2263 993 646 1009

Overall MARD2 9% 8.1% 7.2% 8.8%

%20/203 93% 96.1% 99.4% 95.5%
Size Reduction
1x per Day Calibration N 680 161 95 165
10 Day Use Life Day 1 MARD2 10.7% 10.4% 7.3% 9.8%
Interference Blocking %20/203 84% 90.1% 100% 94.5%
Performance Improvement
1) Represents calibrations required
2) Mean Absolute Relative Difference (MARD) between CGM readings and blood glucose readings
3) Proportion of sensor values within 20 mg/dL of the YSI reference value for glucose levels 80mg/dL and 20% at YSI glucose levels >80mg/dL
* Note: G6 data is pre-pivotal 15
 The Future of CGM Technology

+
Factory Calibrated
14 Day Use Life
Real-Time CGM
Single-use Transmitter
Significant Cost Reduction1

16
1) Cost reduction targeted for second generation sensor
 This is one of the largest public health crises
of our time

700

PRE-DIABETES
400
MILLIONS

NON-INTENSIVE
TYPE 2

INSULIN INTENSIVE
(TYPE 1 + TYPE 2)
0
1980 2014 2025
17
Source: NCD Risk Factor Collaboration, Published April 2016
We have made progress

$700

$600

$500
Revenue ($MM)

$400

$300

$200

$100

$0
2012 2013 2014 2015 2016

18
 But, we have only just started

US Intensive Insulin Population 1 US Total Diabetes Population 1

US CGM
Current US
patients
CGM patients

~3 million US ~30 million

patients US patients
Medicare coverage2
T1 300K (est.)
T2 500K (est.)

T1 / T2 CGM T1 SMBG
T1 / T2 CGM T1 SMBG T2 Intensive SMBG T2 Intensive SMBG T2 Non-Intensive
T2 Non-Insulin
Note: Germany reimbursement decision increases OUS reimbursable patient opportunity by 500,000 intensive insulin patients.
1) Chart source: As of 2016; patient populations are approximate based on internal company estimates.
2) On January 13, 2017, the U.S. Centers for Medicare & Medicaid Services cleared Dexcoms G5 Mobile CGM system as eligible for Medicare & Medicaid coverage.

19
We are driving a paradigm shift in diabetes management
Over time, CGM will help answer more key questions for all patients with diabetes

INSULIN NON-
INTENSIVE INTENSIVE
(T1+T2) (T2)

Is it safe to Are her lifestyle

walk home from changes having an
school? Go to baseball impact?
practice?
Is the $400/month
How will his glucose medicine she is taking
behave in the next few working?
hours?
Will she need to start
Should he give himself using needles in the
insulin now? near future?

20
Illustrative T2 CGM Impact

29% 3X
DECREASE IMPROVEMENT
IN AVERAGE IN
GLUCOSE TIME-IN-RANGE

Time in range 82.7% HIGH Time in range 46.9% HIGH

Average glucose Average glucose
(CGM) 235 mg/dL (CGM) 167mg/dL 17.3% IN RANGE 52.6% IN RANGE

0.0% LOW 0.5% LOW

21
CGM will be a key element of cost reduction
in diabetes management
Many diabetes cost questions are unanswered
- When does a patient move to insulin long-acting/fast acting?
- What is the actual cost and therapeutic benefit of sophisticated insulin delivery systems?
CGM?
- Can we predict and identify those at risk for expensive hospitalizations and keep these
patients from re-admission when they leave and shorten their stay?
- Is the patient actually taking the medications that the system is providing them?
All of our future systems will be designed to produce the data necessary to answer these
and many other questions
We are aiming to reduce our costs on the systems and striving to make CGM available to
everyone

22
A technology that can deliver benefits to every
healthcare constituent through improved outcomes
and reduced costs

PATIENT
Navigate day to day
decisions; feedback loop
for precision understanding
of glucose response
POPULATIONS
Insight on what
PAYOR approaches have driven
impact for others with
Deeply understand
similar physiology
efficacy of treatment to
CLINICIANS better target care to
Navigate who needs more improve outcome, while
attention; develop reducing cost
hyperpersonalized
treatment plans

23
Making it possible to
change their future.

24